|
1
|
Gabriel SE: The epidemiology of rheumatoid
arthritis. Rheum Dis Clin North Am. 27:269–281. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aletaha D and Smolen JS: Effectiveness
profiles and dose dependent retention of traditional disease
modifying anti-rheumatic drugs for rheumatoid arthritis. An
observational study. J Rheumatol. 29:1631–1638. 2002.PubMed/NCBI
|
|
3
|
Smolen JS, Aletaha D, Koeller M, Weisman
MH and Emery P: New therapies for treatment of rheumatoid
arthritis. Lancet. 370:1861–1874. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nurmohamed MT: Newer biological agents in
the treatment of rheumatoid arthritis: do the benefits outweigh the
risks? Drugs. 69:2035–2043. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakajima T, Aono H, Hasunuma T, Yamamoto
K, Shirai T, Hirohata K and Nishioka K: Apoptosis and functional
Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum.
38:485–491. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amano T, Yamasaki S, Yagishita N, et al:
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic
factor for arthropathy. Genes Dev. 17:2436–2449. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bordallo J, Plemper RK, Finger A and Wolf
DH: Der3p/Hrd1p is required for endoplasmic reticulum-associated
degradation of misfolded lumenal and integral membrane proteins.
Mol Biol Cell. 9:209–222. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shearer AG and Hampton RY: Structural
control of endoplasmic reticulum-associated degradation: effect of
chemical chaperones on 3-hydroxy-3-methylglutaryl-CoA reductase. J
Biol Chem. 279:188–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shearer AG and Hampton RY: Lipid-mediated,
reversible misfolding of a sterol-sensing domain protein. EMBO J.
24:149–159. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Toh ML, Marotte H, Blond JL, Jhumka U,
Eljaafari A, Mougin B and Miossec P: Overexpression of synoviolin
in peripheral blood and synoviocytes from rheumatoid arthritis
patients and continued elevation in nonresponders to infliximab
treatment. Arthritis Rheum. 54:2109–2118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao B, Calhoun K and Fang D: The
proinflammatory cytokines IL-1beta and TNF-alpha induce the
expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial
fibroblasts via the Erk1/2-ETS1 pathway. Arthritis Res Ther.
8:R1722006. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao B, Lee SM, Chen A, et al: Synoviolin
promotes IRE1 ubiquitination and degradation in synovial
fibroblasts from mice with collagen-induced arthritis. EMBO Rep.
9:480–485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yagishita N, Yamasaki S, Nishioka K and
Nakajima T: Synoviolin, protein folding and the maintenance of
joint homeostasis. Nat Clin Pract Rheumatol. 4:91–97. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamasaki S, Yagishita N, Sasaki T, et al:
Cytoplasmic destruction of p53 by the endoplasmic
reticulum-resident ubiquitin ligase ‘Synoviolin’. EMBO J.
26:113–122. 2007.PubMed/NCBI
|
|
15
|
Ohta T, Michel JJ, Schottelius AJ and
Xiong Y: ROC1, a homolog of APC11, represents a family of cullin
partners with an associated ubiquitin ligase activity. Mol Cell.
3:535–541. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hughes C, Wolos JA, Giannini EH and Hirsch
R: Induction of T helper cell hyporesponsiveness in an experimental
model of autoimmunity by using nonmitogenic anti-CD3 monoclonal
antibody. J Immunol. 153:3319–3325. 1994.PubMed/NCBI
|
|
17
|
Tomita T, Takeuchi E, Tomita N, et al:
Suppressed severity of collagen-induced arthritis by in vivo
transfection of nuclear factor kappaB decoy oligodeoxynucleotides
as a gene therapy. Arthritis Rheum. 42:2532–2542. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dunn DA and Feygin I: Challenges and
solutions to ultra-high-throughput screening assay miniaturization:
submicroliter fluid handling. Drug Discov Today. 5:84–91. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Moynihan TP, Ardley HC, Nuber U, et al:
The ubiquitin-conjugating enzymes UbcH7 and UbcH8 interact with
RING-finger/IBR motif-containing domains of HHARI and H7-AP1. J
Biol Chem. 274:30963–30968. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hashizume R, Fukuda M, Maeda I, et al: The
RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a
breast cancer-derived mutation. J Biol Chem. 276:14537–14540. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Urano T, Saito T, Tsukui T, et al: Efp
targets 14-3-3 sigma for proteolysis and promotes breast tumour
growth. Nature. 417:871–875. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar
|
|
23
|
Pickart CM: Mechanisms underlying
ubiquitination. Annu Rev Biochem. 70:503–533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deshaies RJ and Joazeiro CA: RING domain
E3 ubiquitin ligases. Annu Rev Biochem. 78:399–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaufman RJ: Orchestrating the unfolded
protein response in health and disease. J Clin Invest.
110:1389–1398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Araki E, Oyadomari S and Mori M:
Endoplasmic reticulum stress and diabetes mellitus. Intern Med.
42:7–14. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cvek B and Dvorak Z: The
ubiquitin-proteasome system (UPS) and the mechanism of action of
bortezomib. Curr Pharm Des. 17:1483–1499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Adams J: Development of the proteasome
inhibitor PS-341. Oncologist. 7:9–16. 2002. View Article : Google Scholar
|
|
29
|
Mitchell BS: The proteasome - an emerging
therapeutic target in cancer. N Engl J Med. 348:2597–2598. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burger AM and Seth AK: The
ubiquitin-mediated protein degradation pathway in cancer:
therapeutic implications. Eur J Cancer. 40:2217–2229. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Q PD: Bortezomib as the first proteasome inhibitor anticancer drug:
current status and future perspectives. Curr Cancer Drug Targets.
11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hopkins AL and Groom CR: The druggable
genome. Nat Rev Drug Discov. 1:727–730. 2002. View Article : Google Scholar
|
|
33
|
Arend WP: Physiology of cytokine pathways
in rheumatoid arthritis. Arthritis Rheum. 45:101–106. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McInnes IB and Schett G: Cytokines in the
pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7:429–442.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stanczyk J, Ospelt C, Gay RE and Gay S:
Synovial cell activation. Curr Opin Rheumatol. 18:262–267. 2006.
View Article : Google Scholar
|
|
36
|
Huber LC, Distler O, Tarner I, Gay RE, Gay
S and Pap T: Synovial fibroblasts: key players in rheumatoid
arthritis. Rheumatology (Oxford). 45669–675. 2006.PubMed/NCBI
|
|
37
|
Knedla A, Neumann E and Muller-Ladner U:
Developments in the synovial biology field 2006. Arthritis Res
Ther. 9:2092007. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hasegawa D, Fujii R, Yagishita N, et al:
E3 ubiquitin ligase synoviolin is involved in liver fibrogenesis.
PLoS One. 5:e135902010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Toh ML, Gonzales G, Koenders MI, et al:
Role of interleukin 17 in arthritis chronicity through survival of
synoviocytes via regulation of synoviolin expression. PLoS One.
5:e134162010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burr ML, Cano F, Svobodova S, Boyle LH,
Boname JM and Lehner PJ: HRD1 and UBE2J1 target misfolded MHC class
I heavy chains for endoplasmic reticulum-associated degradation.
Proc Natl Acad Sci USA. 108:2034–2039. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gomez-Puerta JA and Bosch X: Therapy:
Spleen tyrosine kinase inhibitors - novel therapies for RA? Nat Rev
Rheumatol. 7:134–136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weinblatt ME, Kavanaugh A, Genovese MC,
Musser TK, Grossbard EB and Magilavy DB: An oral spleen tyrosine
kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med.
363:1303–1312. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Koenders MI, Marijnissen RJ, Devesa I, et
al: Tumor necrosis factor-interleukin-17 interplay induces S100A8,
interleukin-1beta, and matrix metalloproteinases, and drives
irreversible cartilage destruction in murine arthritis: rationale
for combination treatment during arthritis. Arthritis Rheum.
63:2329–2339. 2011. View Article : Google Scholar
|
